|Bid||27.61 x 800|
|Ask||30.00 x 800|
|Day's Range||28.51 - 29.98|
|52 Week Range||22.01 - 68.39|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.33|
ShockWave Medical, Inc. (NASDAQ:SWAV) just released its yearly report and things are looking bullish. Revenues and...
SANTA CLARA, Calif., Feb. 13, 2020 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
SANTA CLARA, Calif., Jan. 21, 2020 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
Timing is everything: Here's a look at the big gap in returns for public and private investors in the best performing new Bay Area stocks from last year.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Shockwave Medical, Inc. (“Shockwave”) (SWAV) today announced the pricing of its public offering of 2,481,781 shares of its common stock at a price to the public of $36.25 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Shockwave, are expected to be approximately $90.0 million. The offering is scheduled to close on November 19, 2019, subject to the satisfaction of customary closing conditions.
Shockwave Medical, Inc. (“Shockwave”) (SWAV) today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of common stock are being offered by Shockwave. In addition, Shockwave intends to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of its common stock.
SANTA CLARA, Calif., Nov. 08, 2019 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
SANTA CLARA, Calif., Nov. 07, 2019 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
SANTA CLARA, Calif., Nov. 07, 2019 -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified.
Shockwave Medical, Inc. (SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced commercial availability of the Shockwave S4 Peripheral IVL Catheter in select approved geographies. Shockwave S4 is a low-profile catheter specifically designed to access and treat challenging calcified lesions in below-the-knee (BTK) arteries that are frequently associated with critical limb ischemia (CLI), a serious condition associated with significant morbidity and mortality. Many patients with CLI do not respond well to endovascular treatment, especially when calcium is present, often requiring repeat procedures or even limb amputation.
AmerisourceBergen's (ABC) Q4 earnings are likely to reflect the better-than-expected performance at Pharmaceutical Distribution and higher revenues.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the second quarter. You can find write-ups about an individual hedge fund's trades on numerous financial […]
SANTA CLARA, Calif., Oct. 17, 2019 -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat.
Shockwave Medical, Inc. (SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, unveiled the results of the DISRUPT CAD II study, a European post-market study of coronary IVL, at the Transcatheter Cardiovascular Therapeutics (TCT) 2019 Conference in a “High Impact Clinical Research” session. Coronary IVL is an innovative lesion preparation tool designed to fracture challenging calcium using sonic pressure waves in order to facilitate stent delivery, deployment and optimal expansion. The DISRUPT CAD II outcomes confirmed the initial results from the DISRUPT CAD I study - that IVL may be safely performed with high procedural success and minimal complications.
WeWork parent The We Company has delayed the office-sharing startup's initial public offering until the end of the year. It now either won't come to the public market at all, or come at such a low valuation its venture backers will take a loss. This isn't terribly unusual for 2019.Source: Mitch Hutchinson / Shutterstock.com So far in 2019 there have been 94 IPOs, and 38 of them have shown negative returns.The big winners, like CrowdStrike Holdings (NASDAQ:CRWD), Beyond Meat (NASDAQ:BYND) and Zoom Video Telecommunications (NASDAQ:ZM), have generally come to the market prepared to make a profit. There have also been big medical winners with market caps near $1 billion, like ShockWave Medical (NASDAQ:SWAV) and Turning Point Therapeutics (NASDAQ:TPTX). Most IPOs are still hits -- but the batting average is declining like an aging slugger's.InvestorPlace - Stock Market News, Stock Advice & Trading TipsWeWork is distinguished by the same flaws as Uber (NYSE:UBER) stock and Lyft (NASDAQ:LYFT) stock. It's not making money, even at scale, and current investors are looking at you for a bailout. The WeWork ProblemWeWork's model is to buy lots of office space, fix it up, then sell it at retail in the form of "memberships." As I wrote in August, it's more like LA Fitness than Cloudflare (NYSE:NET), which went public Sept. 13 and is already showing a 25% return. * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars Worse, WeWork's business model is not unique. IWG (OTCMKTS:IWGFF), founded in Belgium back in 1989, has been operating in low-cost suburban office parks for years. It came public at the end of 2016 and only proved itself this year. IWGFF stock is up 92% year-to-date.The difference is that IWG has a market cap of $4.8 billion. WeWork was initially seeking a market cap of $47 billion. Worse, WeWork needs the $3 billion it was trying to raise in order to secure the $6 billion line of credit in order to keep operating.The business model is based on a myth of young workers with startups signing up for prestige "co-working spaces" dressed up with amenities they like. In fact, WeWork has mainly signed up established tech companies seeking contingency space like Salesforce (NYSE:CRM), Cisco (NASDAQ:CSCO) and Facebook (NASDAQ:FB). It's expansion insurance. CEO Adam NeumannMeanwhile t-shirted CEO Adam Neumann has come off as something of a fraud. He isn't a dweeby kid. He's a 40-year old Israeli military veteran who spent big money before earning a dime for shareholders. He tried to score $5.9 million from his own company for trademarking the word "We." This is also a mom-and-pop operation; co-founder Miguel McKelvey gets only six mentions in the U.S. Securities and Exchange Commission Form S-1, against 20 mentions for Neumann's wife Rebekah.While portraying a handsome young family man on TV, Neumann also created a fraternity culture that drew a sexual harassment suit last year.Worse, it's clear the business model is not yet working. WeWork lost $1.9 billion in 2018, then another $904 million for the first six months of 2019, on revenue of $1.5 billion. The Bottom Line on the WeWork IPOThe real loser is SoftBank (OTCMKTS:SFTBF) and its Vision Fund. It brought $100 billion to the party in order control the technology of the future -- and it's trying to raise another $100 billion. SoftBank founder Masayoshi Son runs the fund, but the money is mostly from sovereign wealth funds in Saudi Arabia and the United Arab Emirates.Son's losers, in addition to WeWork, include Uber, Sprint (NYSE:S) and Slack (NYSE:WORK), which is down more than 30% after coming public in June. Son has called his Vision Fund the ultimate disruptor, but it may be Son who turns out to be the greater fool.Dana Blankenhorn is a financial and technology journalist. He is the author of the mystery thriller, The Reluctant Detective Finds Her Family, available at the Amazon Kindle store. Write him at email@example.com or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this article. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 CBD Stocks to Buy That Are Still Worth Your Investment Dollars * 5 Stocks to Buy With Great Charts * 5 Goldman Sachs Stocks to Buy with Over 20% Upside Potential The post Is Failure in Store for the WeWork IPO? appeared first on InvestorPlace.
CFO of Shockwave Medical Inc (30-Year Financial, Insider Trades) Dan Puckett (insider trades) sold 75,000 shares of SWAV on 09/09/2019 at an average price of $34.71 a share. Continue reading...